Cardio-oncology & otherCohort study
Cardiotoxicity of BRAF/MEK Inhibitors
- Retrospective cohort study
- cancer hospital network
Authors' conclusion
BRAF and MEK inhibitor-associated CTRCD is common.
Study context
- Population
- Patients with melanoma treated with BRAF and MEK inhibitors, June 2017–June 2020
- Participants
- 63 patients
- Outcome
- Incidence of cancer therapy-related cardiac dysfunction (CTRCD; mild, moderate or severe by ICOS definitions)
Main finding
As reported in the abstract
CTRCD
Any cancer therapy-related cardiac dysfunction (CTRCD)
27%
Mild CTRCD
17%
Moderate CTRCD
10%
Severe CTRCD or symptomatic HF
0
Observational data: associations, not effects.
Further findings
| Outcome | Values | P value |
|---|---|---|
| LV internal diameter in diastole, moderate CTRCD vs none | Moderate CTRCD 4.9 ± 0.6 cm · No moderate CTRCD 4.3 ± 0.6 cm | P = 0.023 |
| LV internal diameter in systole, moderate CTRCD vs none | Moderate CTRCD 3.3 ± 0.4 cm · No moderate CTRCD 2.8 ± 0.5 cm | P = 0.039 |
CTRCD by HFA/International Cardio-Oncology Society (ICOS) baseline risk
- CTRCD in patients at "low" and "medium" baseline risk
- 82%
Baseline LVEF and global longitudinal strain, moderate CTRCD vs none
- Not different in patients who developed moderate CTRCD vs those who did not
Original publication
Cardiotoxicity of BRAF/MEK Inhibitors. JACC CardioOncol. Published 6 June 2023. doi:10.1016/j.jaccao.2023.04.004
Summarised from the published abstract; every number is checked against it